MARKET

IMDX

IMDX

Insight Molecular Diagnostics Inc.
NASDAQ
4.500
+0.070
+1.58%
After Hours: 4.500 0 0.00% 16:10 08/12 EDT
OPEN
4.480
PREV CLOSE
4.430
HIGH
4.500
LOW
4.150
VOLUME
279.64K
TURNOVER
--
52 WEEK HIGH
8.51
52 WEEK LOW
2.330
MARKET CAP
147.26M
P/E (TTM)
-3.0348
1D
5D
1M
3M
1Y
5Y
1D
Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
Benzinga · 1d ago
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
Barchart · 1d ago
Insight Molecular Diagnostics (IMDX) Receives a Buy from Lake Street
TipRanks · 1d ago
Michael Matson Reiterates Buy on IMDX, Citing Regulatory Progress, GraftAssure Platform Expansion, and Solid Cash Runway Ahead of Expected 2026 De Novo Approval
TipRanks · 1d ago
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay
TipRanks · 2d ago
Insight Molecular Diagnostics reports Q2 EPS (31c), consensus (23c)
TipRanks · 2d ago
Insight Molecular Diagnostics Inc. Non-GAAP EPS of -$0.23 in-line, revenue of $0.24M misses by $0.2M
Seeking Alpha · 2d ago
Press Release: IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Dow Jones · 2d ago
More
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Webull offers Insight Molecular Diagnostics Inc stock information, including NASDAQ: IMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMDX stock methods without spending real money on the virtual paper trading platform.